Global Muscle Relaxants Drugs Market Size, Share and Trends Analysis Report, By Type of Drugs (Facial Muscle Relaxants, Skeletal Muscle Relaxants, Neuromuscular Blocking Agents), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Forecast (2022-2028)

The global muscle relaxants drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The rising prevalence of lower back pain with the surge in the number of surgeries in the geriatric population and rising healthcare expenditures are expected to boost the growth of the muscle relaxant drugs market during the forecast period. In addition, an increase in the incidence of pain and spasm conditions increased focus on the development of new drugs to treat spasms and pain, approval of standard products, and a growing number of surgeries are some of the other factors contributing to market growth.

 

Neuromuscular blocking agents are powerful muscle relaxants that are commonly used only during surgery to prevent muscle movement. They are structurally related to acetylcholine, a key neurotransmitter in the body, and they cause muscle relaxation by binding to acetylcholine receptors postsynaptically. They prevents neuromuscular transmission and causes muscle paralysis. In November 2019, Zydus Cadila had received the US FDA approval for the generic version of muscle relaxant Cisatracurium Besylate Injection with strengths of 10 mg/5 ml and 200 mg/20 ml given the general anesthesia.

 

Ipsen Biopharmaceuticals Inc., Neurana Pharmaceuticals, Pfizer Inc., Teva Pharmaceuticals, and Zydus Cadila among others are some key players operating in the global muscle relaxants drugs market. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

 

For instance, in September 2019, Ipsen Biopharmaceuticals received United States FDA approval of expanded use of Dysport for injection in the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy.

 

Market Coverage

 

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type of Drugs
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

• Competitive Landscape– Ipsen Biopharmaceuticals Inc., Neurana Pharmaceuticals, Pfizer Inc., Teva Pharmaceuticals, and Zydus Cadilaamong others.

 

Key questions addressed by the report

 

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Muscle Relaxants Drugs Market Report by Segment

 

By Type of Drugs

• Facial Muscle Relaxants
• Skeletal Muscle Relaxants
• Neuromuscular Blocking Agents

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

 

Global Muscle Relaxants Drugs Market Report by Region

 

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa